Your browser doesn't support javascript.
loading
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Ma, Pei; Huang, Ruohan; Gu, Yunru; Fang, Yuan; Wu, Xi; Chen, Dong-Sheng; Zhang, Han-Wu; Gao, Wen; Shu, Yongqian.
Afiliación
  • Ma P; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University.
  • Huang R; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University.
  • Gu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University.
  • Fang Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University.
  • Wu X; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University.
  • Chen DS; Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development, Nanjing, China.
  • Zhang HW; Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development, Nanjing, China.
  • Gao W; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University.
  • Shu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University.
Anticancer Drugs ; 33(10): 1186-1190, 2022 11 01.
Article en En | MEDLINE | ID: mdl-35946569
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved response in all stages of patients with EGFR positive mutations in nonsmall cell lung cancer. However, the primary resistance mechanism of EGFR-TKIs has not been thoroughly revealed. Here, we described a case of a 64-year-old male with lung adenocarcinoma presented primary resistance on osimertinib combined with bevacizumab and platinum-based chemotherapy, next-generation sequencing revealed EGFR exon 21 L858R mutation and MET gene amplification. Afterward, savolitinib monotherapy was started until now, and the treatment was temporarily successful, the last follow-up clinical evaluation was near complete response, the progression-free survival has over 7 months. Our case highlights that EGFR-TKIs may be not the optimal choice for lung adenocarcinoma with primary EGFR -sensitive mutation with MET amplification simultaneously, whereas MET inhibitor alone may be an effective treatment option. In clinical practice, we should fully consider the possibility of primary resistance in EGFR-TKIs administration.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Humans / Male / Middle aged Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Humans / Male / Middle aged Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article